Pfizer remains committed to making its vaccine available in India, a company spokesman said
New Delhi:
Major Pharizer Pharma on Friday said it had decided to withdraw the application for emergency use authorization (EUA) of COVID-19 vaccine from India.
Pfizer was the first pharmaceutical company to apply for an emergency use authorization from the General Drug Controller of India (DCGI) for the COVID-19 vaccine in the country, after obtaining such an authorization in the United Kingdom and Bahrain.
“In accordance with the emergency use license for its COVID-19 vaccine, Pfizer attended the meeting of the Subject Committee of Experts of the Drug Regulatory Authority of India on 3 February. may need, the company has decided to withdraw its application at this time, “a company spokesman said in a statement.
Pfizer will continue to interact with the authority and resubmit the request for approval with additional information as it becomes available in the near future, the statement said.
“Pfizer remains committed to making its vaccine available for use by the Government in India and to follow the necessary path to authorize emergency use that will allow the availability of this vaccine for any future implementation,” the spokesman said.
Pfizer, in its application to the Medicines Regulatory Authority in December 2020, sought permission to import the vaccine for sale and distribution in India, in addition to waiving clinical trials in the Indian population, in accordance with the special provisions of the New Medicines Regulations. and clinical trials, In 2019, official sources said for ITP.
(Except for the title, this story was not edited by NDTV staff and is published in a syndicated stream.)